Which has better earnings and valuation, GH or CI?

Cigna Group has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Cigna Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Guardant Health $982.02M 21.51 -$416.28M -$3.49 N/A Cigna Group $274.90B 0.27 $5.96B $24.17 11.61

Does the media favor GH or CI?

In the previous week, Cigna Group had 4 more articles in the media than Guardant Health. MarketBeat recorded 22 mentions for Cigna Group and 18 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.93 beat Cigna Group's score of 0.92 indicating that Guardant Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Guardant Health 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cigna Group 13 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, LH or GH?

Labcorp has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Labcorp $13.95B 1.81 $876.50M $12.09 25.75 Guardant Health $982.02M 21.51 -$416.28M -$3.49 N/A

Does the media prefer LH or GH?

In the previous week, Labcorp had 3 more articles in the media than Guardant Health. MarketBeat recorded 21 mentions for Labcorp and 18 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.93 beat Labcorp's score of 0.56 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Labcorp 9 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Guardant Health 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GH or DGX?

In the previous week, Guardant Health had 3 more articles in the media than Quest Diagnostics. MarketBeat recorded 18 mentions for Guardant Health and 15 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.19 beat Guardant Health's score of 0.93 indicating that Quest Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Guardant Health 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GH or BTSG?

In the previous week, Guardant Health had 12 more articles in the media than BrightSpring Health Services. MarketBeat recorded 18 mentions for Guardant Health and 6 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.24 beat Guardant Health's score of 0.93 indicating that BrightSpring Health Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Guardant Health 8 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BrightSpring Health Services 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Guardant Health (GH) Competitors

$157.38 -1.65 (-1.04%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$158.75 +1.37 (+0.87%)

As of 09/11/2026 07:59 PM Eastern

Compare

GH vs. CI, LH, DGX, FMS, and BTSG

Should you buy Guardant Health stock or one of its competitors? Guardant Health's main competitors and comparable companies include Cigna Group (CI), Labcorp (LH), Quest Diagnostics (DGX), Fresenius Medical Care AG & Co. KGaA (FMS), and BrightSpring Health Services (BTSG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Guardant Health compare to Cigna Group?

Guardant Health (NASDAQ:GH) and Cigna Group (NYSE:CI) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Cigna Group has a net margin of 2.27% compared to Guardant Health's net margin of -38.33%. Cigna Group's return on equity of 19.75% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-38.33%	N/A	-25.40%
Cigna Group	2.27%	19.75%	5.34%

In the previous week, Cigna Group had 4 more articles in the media than Guardant Health. MarketBeat recorded 22 mentions for Cigna Group and 18 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.93 beat Cigna Group's score of 0.92 indicating that Guardant Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Guardant Health	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cigna Group	13 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Guardant Health currently has a consensus target price of $188.13, suggesting a potential upside of 19.54%. Cigna Group has a consensus target price of $337.10, suggesting a potential upside of 20.17%. Given Cigna Group's higher probable upside, analysts plainly believe Cigna Group is more favorable than Guardant Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.96
Cigna Group	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65

Guardant Health has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Cigna Group has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Cigna Group has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Cigna Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$982.02M	21.51	-$416.28M	-$3.49	N/A
Cigna Group	$274.90B	0.27	$5.96B	$24.17	11.61

92.6% of Guardant Health shares are held by institutional investors. Comparatively, 87.0% of Cigna Group shares are held by institutional investors. 5.6% of Guardant Health shares are held by company insiders. Comparatively, 0.6% of Cigna Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cigna Group beats Guardant Health on 9 of the 17 factors compared between the two stocks.

How does Guardant Health compare to Labcorp?

Labcorp (NYSE:LH) and Guardant Health (NASDAQ:GH) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Labcorp currently has a consensus price target of $336.36, indicating a potential upside of 8.03%. Guardant Health has a consensus price target of $188.13, indicating a potential upside of 19.54%. Given Guardant Health's stronger consensus rating and higher probable upside, analysts plainly believe Guardant Health is more favorable than Labcorp.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.96

Labcorp has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.95B	1.81	$876.50M	$12.09	25.75
Guardant Health	$982.02M	21.51	-$416.28M	-$3.49	N/A

In the previous week, Labcorp had 3 more articles in the media than Guardant Health. MarketBeat recorded 21 mentions for Labcorp and 18 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.93 beat Labcorp's score of 0.56 indicating that Guardant Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Labcorp	9 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Guardant Health	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Labcorp has a net margin of 6.99% compared to Guardant Health's net margin of -38.33%. Labcorp's return on equity of 16.74% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Labcorp	6.99%	16.74%	7.81%
Guardant Health	-38.33%	N/A	-25.40%

Labcorp has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Guardant Health has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 92.6% of Guardant Health shares are owned by institutional investors. 0.8% of Labcorp shares are owned by insiders. Comparatively, 5.6% of Guardant Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Labcorp beats Guardant Health on 9 of the 17 factors compared between the two stocks.

How does Guardant Health compare to Quest Diagnostics?

Guardant Health (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Quest Diagnostics has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$982.02M	21.51	-$416.28M	-$3.49	N/A
Quest Diagnostics	$11.04B	2.35	$992M	$9.42	24.93

Guardant Health presently has a consensus target price of $188.13, indicating a potential upside of 19.54%. Quest Diagnostics has a consensus target price of $236.31, indicating a potential upside of 0.64%. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.96
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54

Guardant Health has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

In the previous week, Guardant Health had 3 more articles in the media than Quest Diagnostics. MarketBeat recorded 18 mentions for Guardant Health and 15 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 1.19 beat Guardant Health's score of 0.93 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Guardant Health	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has a net margin of 9.18% compared to Guardant Health's net margin of -38.33%. Quest Diagnostics' return on equity of 16.01% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-38.33%	N/A	-25.40%
Quest Diagnostics	9.18%	16.01%	7.27%

92.6% of Guardant Health shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 5.6% of Guardant Health shares are held by insiders. Comparatively, 0.9% of Quest Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Guardant Health and Quest Diagnostics tied by winning 8 of the 16 factors compared between the two stocks.

How does Guardant Health compare to Fresenius Medical Care AG & Co. KGaA?

Guardant Health (NASDAQ:GH) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$982.02M	21.51	-$416.28M	-$3.49	N/A
Fresenius Medical Care AG & Co. KGaA	$22.20B	0.54	$1.11B	$1.93	11.58

92.6% of Guardant Health shares are owned by institutional investors. Comparatively, 8.4% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. 5.6% of Guardant Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Guardant Health had 18 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 18 mentions for Guardant Health and 0 mentions for Fresenius Medical Care AG & Co. KGaA. Guardant Health's average media sentiment score of 0.93 beat Fresenius Medical Care AG & Co. KGaA's score of 0.00 indicating that Guardant Health is being referred to more favorably in the media.

Company	Overall Sentiment
Guardant Health	Positive
Fresenius Medical Care AG & Co. KGaA	Neutral

Guardant Health has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Fresenius Medical Care AG & Co. KGaA has a net margin of 4.83% compared to Guardant Health's net margin of -38.33%. Fresenius Medical Care AG & Co. KGaA's return on equity of 9.28% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-38.33%	N/A	-25.40%
Fresenius Medical Care AG & Co. KGaA	4.83%	9.28%	4.16%

Guardant Health presently has a consensus target price of $188.13, suggesting a potential upside of 19.54%. Fresenius Medical Care AG & Co. KGaA has a consensus target price of $23.57, suggesting a potential upside of 5.42%. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Guardant Health is more favorable than Fresenius Medical Care AG & Co. KGaA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.96
Fresenius Medical Care AG & Co. KGaA	5 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.55

Summary

Guardant Health beats Fresenius Medical Care AG & Co. KGaA on 10 of the 17 factors compared between the two stocks.

How does Guardant Health compare to BrightSpring Health Services?

Guardant Health (NASDAQ:GH) and BrightSpring Health Services (NASDAQ:BTSG) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

92.6% of Guardant Health shares are owned by institutional investors. 5.6% of Guardant Health shares are owned by insiders. Comparatively, 2.8% of BrightSpring Health Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BrightSpring Health Services has higher revenue and earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$982.02M	21.51	-$416.28M	-$3.49	N/A
BrightSpring Health Services	$12.91B	0.90	$190.67M	$1.66	35.38

In the previous week, Guardant Health had 12 more articles in the media than BrightSpring Health Services. MarketBeat recorded 18 mentions for Guardant Health and 6 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.24 beat Guardant Health's score of 0.93 indicating that BrightSpring Health Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Guardant Health	8 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BrightSpring Health Services	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Guardant Health has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, BrightSpring Health Services has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

Guardant Health presently has a consensus price target of $188.13, indicating a potential upside of 19.54%. BrightSpring Health Services has a consensus price target of $70.71, indicating a potential upside of 20.39%. Given BrightSpring Health Services' stronger consensus rating and higher probable upside, analysts plainly believe BrightSpring Health Services is more favorable than Guardant Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	1 Strong Buy rating(s)	2.96
BrightSpring Health Services	0 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.10

BrightSpring Health Services has a net margin of 2.55% compared to Guardant Health's net margin of -38.33%. BrightSpring Health Services' return on equity of 16.73% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-38.33%	N/A	-25.40%
BrightSpring Health Services	2.55%	16.73%	5.24%

Summary

BrightSpring Health Services beats Guardant Health on 12 of the 17 factors compared between the two stocks.

Get Guardant Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GH vs. The Competition

Export

Metric	Guardant Health	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.12B	$9.84B	$7.17B	$12.85B
Dividend Yield	N/A	2.61%	2.57%	11.71%
P/E Ratio	-45.09	33.53	274.94	25.27
Price / Sales	21.51	4.89	633.23	90.48
Price / Cash	N/A	125.15	76.65	51.52
Price / Book	-199.22	5.29	10.33	6.20
Net Income	-$416.28M	$313.25M	$3.50B	$358.50M
7 Day Performance	-2.50%	-1.26%	-3.32%	-2.35%
1 Month Performance	-4.68%	-0.98%	-0.41%	-2.77%
1 Year Performance	186.67%	15.13%	19.21%	7.63%

Guardant Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GH Guardant Health	3.3112 of 5 stars	$157.38 -1.0%	$188.13 +19.5%	+177.1%	$21.12B	$982.02M	N/A	2,506	Analyst Forecast
CI Cigna Group	4.8133 of 5 stars	$282.24 -0.1%	$339.45 +20.3%	-8.3%	$74.65B	$274.90B	11.68	67,700	Ex-Dividend Analyst Forecast Insider Trade
LH Labcorp	4.1155 of 5 stars	$326.83 0.0%	$330.00 +1.0%	+11.2%	$26.51B	$13.95B	27.03	71,000	Trending News Analyst Forecast
DGX Quest Diagnostics	4.4194 of 5 stars	$236.75 -0.2%	$235.31 -0.6%	+27.8%	$26.17B	$11.04B	25.13	57,000	Positive News Analyst Forecast Analyst Revision
FMS Fresenius Medical Care AG & Co. KGaA	2.176 of 5 stars	$22.66 flat	$23.57 +4.0%	-11.6%	$12.17B	$22.20B	11.74	1,488

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GH) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Guardant Health (GH) Competitors

GH vs. CI, LH, DGX, FMS, and BTSG

How does Guardant Health compare to Cigna Group?

Summary

How does Guardant Health compare to Labcorp?

Summary

How does Guardant Health compare to Quest Diagnostics?

Summary

How does Guardant Health compare to Fresenius Medical Care AG & Co. KGaA?

Summary

How does Guardant Health compare to BrightSpring Health Services?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GH vs. The Competition

Guardant Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Guardant Health (GH) Competitors

GH vs. CI, LH, DGX, FMS, and BTSG

How does Guardant Health compare to Cigna Group?

Is GH or CI more profitable?

Does the media favor GH or CI?

Do analysts recommend GH or CI?

Which has more volatility and risk, GH or CI?

Which has better earnings and valuation, GH or CI?

Do institutionals & insiders have more ownership in GH or CI?

Summary

How does Guardant Health compare to Labcorp?

Do analysts recommend LH or GH?

Which has stronger valuation and earnings, LH or GH?

Does the media prefer LH or GH?

Is LH or GH more profitable?

Which has more volatility & risk, LH or GH?

Do institutionals and insiders believe in LH or GH?

Summary

How does Guardant Health compare to Quest Diagnostics?

Which has preferable valuation & earnings, GH or DGX?

Do analysts rate GH or DGX?

Which has more volatility & risk, GH or DGX?

Does the media favor GH or DGX?

Is GH or DGX more profitable?

Do institutionals & insiders hold more shares of GH or DGX?

Summary

How does Guardant Health compare to Fresenius Medical Care AG & Co. KGaA?

Which has better earnings & valuation, GH or FMS?

Do institutionals and insiders have more ownership in GH or FMS?

Does the media refer more to GH or FMS?

Which has more risk & volatility, GH or FMS?

Is GH or FMS more profitable?

Do analysts prefer GH or FMS?

Summary

How does Guardant Health compare to BrightSpring Health Services?

Do institutionals & insiders believe in GH or BTSG?

Which has better valuation and earnings, GH or BTSG?

Does the media favor GH or BTSG?

Which has more volatility and risk, GH or BTSG?

Do analysts recommend GH or BTSG?

Is GH or BTSG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GH vs. The Competition

Guardant Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools